Nemea (Clozapine)

Clozapine blocks dopamine D2 and serotonin 5‑HT2A receptors while also affecting adrenergic, histaminergic and muscarinic receptors. This broad receptor antagonism helps reduce psychotic symptoms and stabilise mood in severe psychiatric disorders.

The dosage of clozapine is individualized. A prescriber determines the appropriate starting dose and titration schedule based on the patient’s clinical response, prior treatment history and laboratory monitoring.

Safety data for clozapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Nemea, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Clozapine is distinguished by its efficacy in treatment‑resistant schizophrenia, where many other antipsychotics fail. However, it carries a higher risk of serious hematologic and metabolic side effects, requiring regular blood monitoring, unlike many first‑generation or other atypical agents.

Store Nemea at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct heat, and discard any product that appears discoloured or damaged.

Nemea is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole; do not crush, split or chew unless specifically instructed.

The most critical risks include agranulocytosis (a severe drop in white‑blood‑cell count), myocarditis, seizures and metabolic disturbances such as hyperglycaemia. Regular blood monitoring and clinical assessment are essential to detect these complications early.

Clozapine is contraindicated in patients with a known hypersensitivity to the drug, a history of clozapine‑induced agranulocytosis, uncontrolled epilepsy, severe cardiovascular disease, or those currently receiving myelosuppressive therapy. A prescriber must evaluate each patient’s medical history before initiating therapy.